

Publikationsliste

PD Dr. med. **Andreas D. Kistler**

Stand 20.02.2019

Originalarbeiten (peer reviewed)

1. Diebold M, **Kistler AD**. Evaluation of Iron Stores In Hemodialysis Patients On Maintenance Ferric Carboxymaltose Dosing. *BMC Nephrology*, *in press*
2. Kölling M, Seeger H, Haddad G, **Kistler A**, Nowak A, Faulhaber-Walter R, Kielstein J, Haller H, Fliser D, Mueller T, Wüthrich RP, Lorenzen JM. The Circular RNA *ciRs-126* Predicts Survival in Critically Ill Patients With Acute Kidney Injury. *Kidney Int Rep*. 2018;3(5):1144-1152.
3. Kölling M, Genschel C, Kaucsar T, Hübner A, Rong S, Schmitt R, Sörensen-Zender I, Haddad G, **Kistler A**, Seeger H, Kielstein JT, Fliser D, Haller H, Wüthrich R, Zörnig M, Thum T, Lorenzen J. Hypoxia-induced long non-coding RNA Malat1 is dispensable for renal ischemia/reperfusion-injury. *Sci Rep*. 2018;8(1):3438
4. Pejchinovski M, Siwy J, Metzger J, Dakna M, Mischak H, Klein J, Jankowski V, Bae KT, Chapman AB, **Kistler AD**. Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression. *Nephrol Dial Transplant*. 2017;32(3):487-497
5. Yu H, **Kistler A**, Faridi MH, Meyer JO, Trynieszewska B, Mehta D, Yue L, Dryer S, Reiser J. Synaptopodin Limits TRPC6 Podocyte Surface Expression and Attenuates Proteinuria. *J Am Soc Nephrol*. 2016;27(11):3308-3319
6. Koenig KF, Ribi C, Radosavac M, Zulewski H, Trendelenburg M; **Swiss SLE cohort study (SSCS)**. Prevalence of vascular disease in systemic lupus erythematosus compared with type-1 diabetes mellitus: a cross-sectional study of two cohorts. *Lupus*. 2015;24(1):58-65.
7. **Kistler AD**, Caicedo A, Abdulreda MH, Faul C, Kerjaschki D, Berggren PO, Reiser J, Fornoni A. In vivo imaging of kidney glomeruli transplanted into the anterior chamber of the mouse eye. *Sci Rep*. 2014;4:3872
8. **Kistler AD**, Singh G, Pippin J, Altintas MM, Yu H, Fernandez IC, Gu C, Wilson C, Srivastava SK, Dietrich A, Walz K, Kerjaschki D, Ruiz P, Dryer S, Sever S, Dinda AK, Faul C, Shankland SJ, Reiser J. TRPC6 protects podocytes during complement-mediated disease. *J Biol Chem*. 2013;288(51):36598-609
9. **Kistler AD**, Serra AL, Siwy J, Poster D, Krauer F, Torres VE, Mrug M, Grantham JJ, Bae KT, Bost JE, Mullen W, Wüthrich RP, Mischak H and Chapman AB. Urinary proteomic biomarkers enable diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multi-centric study. *PLoS One*. 2013;8(1):e53016
10. Braun M, Young J, Reiner CS, Poster D, Krauer F, **Kistler AD**, Kristanto P, Wang X, Liu Y, Loffing J, Andreisek G, von Eckardstein A, Senn O, Wüthrich RP, Serra AL. Low-Dose Oral

- Sirolimus and the Risk of Menstrual-Cycle Disturbances and Ovarian Cysts: Analysis of the Randomized Controlled SUISSE ADPKD Trial. *PLoS One*. 2012;7(10):e45868
11. Mohebbi N, Vargas-Poussou R, Hegemann SC, Schuknecht B, **Kistler AD**, Wüthrich RP, Wagner CA. Homozygous and compound heterozygous mutations in the ATP6V1B1 gene in patients with renal tubular acidosis and sensorineural hearing loss. *Clin Genet*. 2013 Mar;83(3):274-8
 12. Pavik I, Jaeger P, Ebner L, Poster D, Krauer F, **Kistler AD**, Rentsch K, Andreisek G, Wagner CA, Devuyst O, Wüthrich RP, Schmid C, Serra AL. Soluble Klotho and Autosomal Dominant Polycystic Kidney Disease. *Clin J Am Soc Nephrol*. 2012;7(2):248-57
 13. Yaddanapudi S, Altintas MM, **Kistler AD**, Fernandez I, Möller CC, Wei C, Peev V, Flesche JB, Forst AL, Li J, Patrakka J, Xiao Z, Grahammer F, Schiffer M, Lohmüller T, Reinheckel T, Gu C, Huber TB, Ju W, Bitzer M, Rastaldi MP, Ruiz P, Tryggvason K, Shaw AS, Faul C, Sever S, Reiser J. CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. *J Clin Invest*. 2011;121(10):3965-80.
 14. Nijenhuis T, Sloan AJ, Hoenderop JG, Flesche J, van Goor H, **Kistler AD**, Bakker M, Bindels RJ, de Boer RA, Möller CC, Hamming I, Navis G, Wetzels JF, Berden JH, Reiser J, Faul C, van der Vlag J. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. *Am J Pathol*. 2011;179(4):1719-32.
 15. **Kistler AD**, Siwy J, Breunig F, Jeevaratnam P, Scherl A, Mullen W, Warnock DG, Wanner C, Hughes DA, Mischak H, Wüthrich RP, Serra AL. A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy. *PLoS One*. 2011;6(6):e20534.
 16. Bolliger MF, Zurlinden A, Lüscher D, Bütikofer L, Shakhova O, Francolini M, Kozlov SM, Cinelli P, Stephan A, **Kistler AD**, Rüllicke T, Pelczar P, Ledermann B, Fumagalli G, Gloor SM, Kunz B, Sonderegger P. Specific proteolytic cleavage of agrin regulates the maturation of the neuromuscular junction. *J Cell Sci*. 2010;123(22):3944-55.
 17. Pavik I, Jaeger P, **Kistler AD**, Poster D, Krauer F, Weder Cavelti C, Rentsch KM, Wüthrich RP, Serra AL. Elevated FGF23 levels in ADPKD patients with apparent renal leak of phosphate: A new manifestation of ADPKD. *Kidney Int*. 2011;79(2):234-40.
 18. Serra AL, Poster D, **Kistler AD**, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP. Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease. *N Engl J Med* 2010;363:820-829
 19. Serra AL, **Kistler AD**, Poster D, Krauer F, Senn O, Raina S, Pavik I, Rentsch K, Regener A, Weishaupt D, Wüthrich RP. Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease. *Nephrol Dial Transplant*. 2009;24(11):3334-42.
 20. Poster D and **Kistler AD (equal contribution)**, Krauer F, Blumenfeld JD, Rennert H, Weishaupt D, Wüthrich RP, Serra AL. Kidney function and volume progression in unilateral autosomal dominant polycystic kidney disease with contralateral renal agenesis or hypoplasia: a case series. *Am J Kidney Dis*. 2009;54(3):450-8.
 21. **Kistler AD**, Mischak H, Poster D, Dakna M, Wüthrich RP, Serra AL. Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. *Kidney Int*. 2009;76(1):89-96.
 22. **Kistler AD**, Poster D, Krauer F, Weishaupt D, Raina S, Senn O, Binet I, Spanaus K, Wüthrich RP, Serra AL. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. *Kidney Int*. 2009;75(2):235-41.

23. Stephan A, Mateos JM, Kozlov SV, Cinelli P, **Kistler AD**, Hettwer S, Rüllicke T, Streit P, Kunz B, Sonderegger P. Neurotrypsin cleaves agrin locally at the synapse. *FASEB J.* 2008;22(6):1861-73.
24. Serra AL, **Kistler AD**, Poster D, Strucker M, Wüthrich RP, Weishaupt D, Tschirch F. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. *BMC Nephrol.* 2007;8:13

Case reports

1. Frei A, **Kistler AD**. Zu viel D(es Guten). *Swiss Med Forum.* 2018;18(43):885-888
2. Sandner D, Bundi B, Müller D, Müller MK, **Kistler AD**. Vom Paintball gezeichnet. *Praxis (Bern 1994).* 2018;107(15):845-847
3. **Kistler AD**, Schwarz U, Dalmau J, Rudiger A. Laparoscopic epilepsy surgery. *Intensive Care Med.* 2010;36(2):367-8.
4. **Kistler AD**, Poster D, Wüthrich RP, Serra AL. Hydronephrosis in autosomal dominant polycystic kidney disease. *Kidney Int.* 2009;76(12):1297.
5. Hofbauer GF, Marcollo-Pini A, Corsenca A, **Kistler AD**, French LE, Wüthrich RP, Serra AL. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. *Br J Dermatol.* 2008;159(2):473-5.

Reviews

1. Seeger H, **Kistler AD**. Nephrologische Diagnostik mit der Toolbox des Hausarztes. *Therapeutische Umschau, in press*
2. Flury S, **Kistler AD**. (Wie) kann die Progression chronischer Nierenerkrankungen verlangsamt werden? *Therapeutische Umschau, in press*
3. Diebold M, **Kistler AD**. Röntgenkontrastmittel – zu Unrecht verteufelt? *Therapeutische Umschau, in press*
4. Diebold M, **Kistler AD**. CME: Abklärung bei Hypokaliämie. *Praxis (Bern 1994). In press*
5. **Kistler AD**, Andreisek G. Recommendations for Diagnostic and Prognostic Evaluation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) with a Focus on Imaging. *Praxis (Bern 1994).* 2018 Jan;107(3):158-164.
6. **Kistler AD**, Bonny O, Fuster D, Martin PY, Devuyst O. Zulassung von Tolvaptan (Jinarc®) in der Schweiz zur Behandlung der Autosomal Dominanten Polyzystischen Nierenerkrankung (ADPKD): ein Paradigmenwechsel. *Schweiz Med Forum* 2017;17(14):336-339
7. Lüthi L, **Kistler A**, Nowak A. CME: Hyperkaliämie bei Patienten mit chronischer Hämodialyse. *Praxis (Bern 1994).* 2017;106(11):561-570.
8. **Kistler AD**. Paraneoplastische membranöse Nephropathie. *Nepro-News* 2016;6:9
9. **Kistler AD**. Chronische Niereninsuffizienz: Wie lässt sich die Progression verhindern? *Hausarzt Praxis* 2016;11(12):35-38
10. **Kistler AD**. Das atypische hämolytisch-urämische Syndrom (aHUS): neue Erkenntnisse zur Pathogenese mit Implikationen für die Therapie. *Praxis (Bern 1994).* 2016;105(7):389-

96

11. **Kistler AD**. Interstitielle Nephritis. *Swiss Medical Forum* 2016;16(5):108-113
12. **Kistler AD**, Huynh-Do U. Lupusnephritis. *Rheuma Schweiz* 2016;1:26-30
13. Bock A, Jehle AW, Fischer A, Farese S, **Kistler AD**, Meffert G, Schönholzer C, Müller R, Spirk D, Ambühl P. CKD-MBD: Was tun, wenn die Evidenz fehlt? *Schweiz Med Forum* 2015;15(38):848-851
14. Wüthrich RP, **Kistler AD**. Blutdruckkontrolle bei Patienten mit polyzystischer Nierenerkrankung. *Der Nephrologe* 2015;10:201-6
15. **Kistler AD**. Lupusnephritis. *Ther Umsch.* 2015;72(3):171-7
16. **Kistler AD**, Wüthrich RP. Welche Therapien können die Progression der chronischen Niereninsuffizienz wirksam verlangsamen? *Swiss Medical Forum*, 2015;15(11):251-256
17. Daikeler T, **Kistler AD**, Martin P-Y, Vogt B, Huynh-Do U. The role of rituximab in the treatment of ANCA-associated vasculitides (AAV). *Swiss Med Wkly.* 2015 Feb 6;145:w14103
18. **Kistler AD**. Update Lupusnephritis - Pathologie, Diagnose, Therapie. *Leading Opinions Innere Medizin* 2013;5:49-51
19. Heeringa S, **Kistler AD**. Utility of Urinary Biomarkers in Fabry Disease. *CML – Lysosomal Storage Diseases* 2013;11(4):108-17
20. **Kistler AD**. Albuminurie beim Diabetiker: praktisches Management. *Praxis (Bern 1994)*. 2013;102(20):1229-35
21. **Kistler AD**, Serra AL. Zystische Nierenerkrankungen: neue diagnostische Aspekte. *Der Nephrologe. Der Nephrologe* 2010;5(5):375-83
22. Wüthrich RP, **Kistler AD**, Serra AL. Inhibition of mTOR and impact on autosomal dominant polycystic kidney disease. *Transplant Proc.* 2010;42(9 Suppl):S44-6
23. **Kistler AD**, Peev V, Forst AL, El Hindi S, Altintas MM, Reiser J. Enzymatic disease of the podocyte. *Pediatr Nephrol.* 2010;25(6):1017-23.
24. Reiser J, Gupta V, **Kistler AD**. Toward the development of podocyte-specific drugs. *Kidney Int.* 2010;77(8):662-8.
25. Wüthrich RP, Serra AL, **Kistler AD**. Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy. *Kidney Blood Press Res.* 2009;32(5):380-7.

Editorials, commentaries und letters

1. **Kistler AD**. Niereninsuffizienz – eine verborgene Epidemie (Editorial zu einer als Gastherausgeber gestalteten Ausgabe). *Therapeutische Umschau, in press*
2. **Kistler AD**. Eculizumab in atypical hemolytic-uremic syndrome. *N Engl J Med.* 2013;369(14):1378
3. **Kistler AD**, Altintas MM, Reiser J. Podocyte GTPases regulate kidney filter dynamics. *Kidney Int.* 2012;81(11):1053-5
4. **Kistler AD**, Faul C, Reiser J. TRPC6 in podocytes: questions and commentary on the article by Jiang et al., 'Over-expressing transient receptor potential cation channel 6 in podocytes induces cytoskeleton rearrangement through increases of intracellular Ca²⁺ and RhoA activation'. *Exp Biol Med (Maywood)*. 2011;236(12):1361

5. **Kistler AD**, Reiser J. Maximal "CD80-uria" with Minimal Change. *Kidney Int.* 2010;78(3):236-8

Buchkapitel

1. **Kistler AD** und Brandt S. Kapitel «Niere» in: *Pathomaps*, Springer, 2019
2. Wüthrich RP, **Kistler AD**, Rodriguez D, Kapoor S, Mei C. Blood Pressure Control for Polycystic Kidney Disease, In Li X, editor. *Polycystic Kidney Disease [Internet]*. Brisbane (AU): Codon Publications; 2015 Nov. Chapter 5.
3. **Kistler AD**. Traditional and Proteomic Biomarkers of Autosomal Dominant Polycystic Kidney Disease (ADPKD). In: *General Methods in Biomarker Research and their Applications*. Springer, Netherlands 2015, DOI 10.1007/978-94-007-7740-8_48-1

Abstracts

Über 50 Abstracts (poster presentations und oral presentations) an nationalen und internationalen Kongressen